
Discovering, developing, and distributing pharmaceutical products for invasive fungal infections in humans. Based in Durham, US.
SCYNEXIS, Inc., founded in Durham, North Carolina, is a biotechnology company focused on discovering, developing, and distributing pharmaceutical products for the treatment of invasive fungal infections. The company's core mission is to address unmet medical needs in fungal infection treatments through innovative solutions. SCYNEXIS offers BREXAFEMME for vulvovaginal candidiasis (VVC) and recurrent VVC, and its lead product candidate, Ibrexafungerp, targets various severe fungal infections including invasive candidiasis and aspergillosis.
Notable affiliations include research collaborations with Merck Sharp & Dohme Corp. SCYNEXIS has achieved significant milestones, such as the FDA approval of BREXAFEMME, marking a new advancement in antifungal treatments. The company's impact is underscored by its commitment to providing effective therapies for challenging fungal infections, thereby improving patient outcomes and addressing critical gaps in the current treatment landscape.

Syneos Health
syneoshealth.com

Synereca Pharmaceuticals

Insmed
insmed.com

Sydnexis
sydnexis.com

SelectX Pharmaceuticals

Sequella

MiniVax

SphynKx Therapeutics

Aptinyx
aptinyx.com

Escient Pharmaceuticals

Chimerix

Microbiotix
microbiotix.com

Exodos Life Sciences
exodosls.com

Taxis Pharmaceuticals
taxispharma.com

Sonexa Therapeutics
Companies similar to Scynexis include Syneos Health, Synereca Pharmaceuticals, Insmed and Sydnexis.
Scynexis was founded in 1999.
Scynexis' headquarters is located in Jersey City, NJ, US.
Scynexis' most recent funding round was for $45M (USD) in April 2022.
As of Apr 22, 2022, Scynexis has raised a total of $279.3M (USD).
Scynexis has 56 employees as of Feb 6, 2024.